- Hypercoagulability in hematological malignancies
M.H.J. van Oers
- Award date
- 4 September 2015
- Number of pages
- Document type
- PhD thesis
- Faculty of Medicine (AMC-UvA)
Patients with cancer are at high risk for venous thrombosis, the undesired formation of blood clots within the veins. Historically, this high risk was mainly attributed to patients with solid tumors, but recent studies have indicated that the risk is at least as high or even higher in patients with hematological malignancies, such as lymphoma, multiple myeloma and leukemia, especially acute lymphoblastic leukemia. Venous thrombosis can cause life-long morbidity or can be fatal, and requires anticoagulant treatment with the accompanying risk of bleeding. Moreover, thrombosis can lead to suboptimal treatment of the malignancy, due to the necessity to interrupt, delay or even discontinue treatment.
In this thesis, the incidence, pathogenesis and prevention of venous thrombosis are investigated in patients with hematological malignancies. This thesis consists of three parts; In Part I, the relationship between venous thrombosis and cancer is highlighted and illustrated with a fascinating case. Part II focuses on two distinct risk factors for hypercoagulability, the JAK2V617F mutation and nucleosomes. In Part III, the incidence, pathogenesis and prevention of venous thrombosis in acute lymphoblastic leukemia are investigated. The studies in this thesis aim to increase insight in the risk factors and mechanisms behind the hypercoagulable state in hematological malignancies. This will help to improve prevention of venous thrombosis in patients with a hematological malignancy, and may benefit the efficacy and safety of anti-cancer treatment, particularly in acute lymphoblastic leukemia.
- Research conducted at: Universiteit van Amsterdam
Thesis (complete) (Embargo up to and including 1 January 2019)
Chapter 3: Leukemic transformation of essential thrombocythemia masked by recurrence of venous thromboembolism; A case report (Embargo up to and including 1 January 2019)
Chapter 7: Circulating nucleosomes, neutrophil activation and development of venous thrombosis in patients with multiple myeloma (Embargo up to and including 1 January 2019)
Chapter 8: Age is the main clinical risk factor for venous thromboembolism within a large cohort of children with acute lymphoblastic leukemia (Embargo up to and including 1 January 2019)
Chapter 12: Prophylaxis for venous thromboembolism during asparaginase therapy in patients treated for acute lymphoblastic leukemia (Embargo up to and including 1 January 2019)
Chapter 13: Prevention of venous thromboembolism with low-molecularweight heparin in adults treated for acute lymphoblastic leukemia; HOVON-100 thromboprophylaxis study protocol (Embargo up to and including 1 January 2019)
Chapter 14: Summary and Future perspectives (Embargo up to and including 1 January 2019)
Chapter 15: Nederlandse samenvatting (Embargo up to and including 1 January 2019)
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.